biotech · Propionic Acidemia · Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency
SOM Biotech
Moderna Biotech Spain
Moderna Biotech Spain is a biotech organization headquartered in EU. Primary therapeutic focus areas include Propionic Acidemia, Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency, Glycogen storag
Company details
- Status
- Public
- HQ
- Barcelona, ES
- Founded
- 2009
- Employees
- 14
- Programs
- 10
- Drugs
- 27
- Patents
- 0
Quick answer
Moderna Biotech Spain is a biotech organization headquartered in EU. Primary therapeutic focus areas include Propionic Acidemia, Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency, Glycogen storage disease type 1a (GSD1a), Seasonal Influenza, Participants with Phenylketonuria. NovaPharmaNews links 10 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (6), phase 3 (3), approved (1).
Company snapshot
For additional information: [email protected]
- 10 active pipeline program(s) linked via ClinicalTrials.gov.
- 10 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for SOM Biotech. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
- trial_data
Biotech's Future: Insights from Jeremy Levin
- approval
Moderna Stock Rises as EMA Committee Backs New RSV Vaccine: Key Implications for Investors and BD Teams
- approval
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
- approval
Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses
Recent coverage
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.
Moderna Stock Rises as EMA Committee Backs New RSV Vaccine: Key Implications for Investors and BD Teams
Moderna Inc. stock (MRNA) rose 5.9% after an EMA committee backed its new RSV vaccine candidate. This analysis explains what changed, why it matters for pharma BD and investors, and what to watch next.
Biotech's Future: Insights from Jeremy Levin
Structured plan for Biotech's Future: Insights from Jeremy Levin
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.
Top assets
Lead pipeline drugs
- approved
- approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 2
Momentum
Proprietary activity score for SOM Biotech.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for SOM Biotech.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is SOM Biotech?
-
Is SOM Biotech publicly traded?
-
What drugs does SOM Biotech develop or market?
-
What are the latest developments for SOM Biotech?
-
What therapeutic areas does SOM Biotech focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.